Alvadermo

Alvadermo is a clinical-stage biotechnology company dedicated to developing innovative topical therapies for chronic inflammatory skin diseases. Founded in 2022 and headquartered in Barcelona, Spain, the company was established by a team of dermatology experts with extensive experience at Almirall. Alvadermo's lead program, ALV-101, is a potent and selective topical Janus kinase (JAK) inhibitor designed to treat conditions such as atopic dermatitis and psoriasis. The company focuses on optimizing drug delivery to ensure high local efficacy while minimizing systemic exposure and associated side effects. By leveraging its deep expertise in skin biology and formulation science, Alvadermo aims to provide safer and more effective treatment options for patients suffering from debilitating skin conditions.